Eli Lilly’s triple agonist retatrutide produced industry-leading weight-loss results in late-stage testing, with Phase 3 readouts showing roughly mid-to-high‑20s percent mean body-weight reduction at ~68 weeks across reports. The company presented pooled and dose-specific data showing substantial and sustained weight loss alongside meaningful symptom relief such as reduced knee pain in obesity cohorts. The readouts prompted analysts and competitors to recalibrate obesity programs and commercial forecasts: high efficacy may drive rapid uptake but also sharp scrutiny of safety and discontinuation rates. Data flagged tolerability issues at higher doses, with discontinuations in some arms; regulators and payers will weigh risk–benefit, long-term safety, and real-world adherence. For readers: triple agonists target GLP-1, GIP and glucagon receptors to amplify metabolic effects.